Studies have shown that the cooperation of LKB1 deficiency and GTPase KRas (KRAS) activation could promote cancer progression through the mTOR-dependent induction of the serine–glycine one-carbon pathway, leading to increased SAM production. Here, KRAS is linked to cancer.